Sandoz bets big on biosimilars as US tariff threat looms
US 100% generic tariff threat Trump threatened 100% tariffs on generic medicines, a direct risk to Sandoz's low-margin generics business. Its CEO warned tariffs would not bring production to the US and could disrupt supply of vital medicines, weighing on the shares.
A major policy threat to Sandoz's core generics business and a real counterweight to the positive news.
Strong H1 results and raised margin guidance First-half sales rose 10% to $5.76bn, with biosimilars up 25% and now a third of sales. Profit margins expanded and full-year margin guidance was raised, showing the biosimilar bet is paying off and supporting the shares.
Hard financial results that confirm the growth story and underpin the stock.
Bio100 strategy and pipeline expansion Sandoz unveiled Bio100, aiming to lead biosimilars by 2040 with over 100 products and to more than double sales in a decade. It added a Henlius partnership worth up to $322m and a $300m Slovenia plant, giving investors a long-term growth plan.
The strategy and pipeline deals set the long-term direction that drives the investment case.
New market approvals and Thailand talks Brazil approved Sandoz's semaglutide diabetes drug Owozy for launch in a $1.8bn market, and Thailand plans a cooperation deal within weeks to draw Sandoz investment. Both widen its reach, though near-term financial impact is limited.
Shows geographic expansion that adds future sales, a smaller but genuine positive driver.